Table 2.
Medication history
| SSNS | SRNS | |
|---|---|---|
| Relapse/remission patterns | ||
| Normal responders | 40% (49/121) | 0% (0/67) |
| Frequent relapsers | 58% (70/121) | |
| Relapses/year | 5.9 ± 3.0 | 7.0 ± 1.7 |
| Persistent proteinuria | 6% (7/121) | 85% (57/67) |
|
MMF | ||
| Usage | 46% (56/121) | 15% (10/67) |
| Duration of use, months | 17.9 ± 12.4 | 18.1 ± 13.5 |
| Response | ||
| CR | 63% (32/51) | 45% (4/9) |
| PR | 2% (1/51) | 22% (2/9) |
| NR | 35% (18/51) | 33% (3/9) |
|
Tacrolimus | ||
| Usage | 19% (23/121) | 34% (23/67) |
| Duration of use, months | 31.7 ± 25.6 | 20.5 ± 19.3 |
| Response | ||
| CR | 78% (18/23) | 54% (12/22) |
| PR | 18% (4/23) | 23% (5/22) |
| NR | 4% (1/23) | 23% (5/22) |
|
Rituximab | ||
| Usage | 5% (6/121) | 6% (4/67) |
| Response | ||
| CR | 83% (5/6) | 25% (1/4) |
| PR | 0% (0/6) | 0% (0/4) |
| NR | 17% (1/6) | 75% (3/4) |
|
Cyclosporine | ||
| Usage | 14% (17/121) | 19% (13/67) |
| Duration of use, months | 23.9 ± 21.0 | 29.0 ± 42.0 |
| Response | ||
| CR | 57% (8/14) | 31% (4/13) |
| PR | 0% (0/14) | 23% (3/13) |
| NR | 43% (6/14) | 46% (6/13) |
|
Cyclophosphamide | ||
| Usage | 9% (11/121) | 6% (4/67) |
| Duration of use, months | 2.7 ± 0.8 | 3.0 ± 9.5 |
| Response | ||
| CR | 44% (4/9) | 0% (0/3) |
| PR | 0% (0/9) | 33% (1/3) |
| NR | 56% (5/9) | 67% (2/3) |
|
ACEi/ARB | ||
| Usage | 20% (24/121) | 65% (44/67) |
CR = Complete remission; PR = partial remission; NR = no remission.